Latest News

  • Alkermes to Take Part in SVB Leerink 10th Annual Global Healthcare Conference Read More
  • Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2020 and Provides Financial Expectations for 2021 Read More
  • Alkermes to Host Conference Call to Discuss Fourth Quarter and Year-End 2020 Financial Results Read More
  • NIDA-Funded Study Evaluating Extended-Release Injectable Naltrexone Plus Bupropion for the Treatment of Methamphetamine Use Disorder Published in New England Journal of Medicine Read More

Investors

ALKS investor relations
Learn more Learn More

Pipeline

patient focused CNS disorder treatments
See Our Approach See Our Approach

COVID-19

Response to Current Events
COVID-19 Read Our Response